What is the recommended initial dose of Ryzodeg (insulin degludec/insulin aspart) for an insulin‑naïve adult with type 2 diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ryzodeg Initial Dose for Insulin-Naïve Adults with Type 2 Diabetes

The recommended starting dose of Ryzodeg (insulin degludec/insulin aspart) for insulin-naïve adults with type 2 diabetes is 10 units once daily, administered with the largest or most carbohydrate-rich meal of the day. 1

Starting Dose and Administration

  • Begin with 10 units once daily with the meal containing the most carbohydrates 1
  • This starting dose applies regardless of body weight or baseline glucose levels in most insulin-naïve patients 1
  • The fixed-ratio formulation provides both basal coverage (from insulin degludec) and prandial coverage (from insulin aspart) in a single injection 1

Dose Titration Strategy

  • Titrate weekly in 2-unit increments based on fasting plasma glucose measurements 1
  • Adjust the dose according to individualized fasting glucose targets, typically aiming for 90-150 mg/dL in most adults 2, 3
  • Continue weekly adjustments until fasting glucose targets are consistently achieved 1

Clinical Context for Insulin Initiation

The decision to start Ryzodeg should be guided by specific clinical indicators 4:

  • A1C >10% (>86 mmol/mol) or blood glucose ≥300 mg/dL (≥16.7 mmol/L) 4
  • Presence of symptomatic hyperglycemia 4, 3
  • Evidence of ongoing catabolism such as unexpected weight loss 4

Important Considerations

Concomitant medications require dose adjustments 1:

  • Sulfonylureas frequently need discontinuation or dose reduction when starting Ryzodeg to minimize hypoglycemia risk 1
  • When adding SGLT2 inhibitors or GLP-1 receptor agonists, the Ryzodeg dose may need reduction 1
  • Metformin should generally be continued when initiating insulin therapy 4

Timing flexibility is a practical advantage 1:

  • Ryzodeg can be administered with any main meal, but consistency with the largest carbohydrate-containing meal optimizes prandial coverage 1
  • The meal timing can be adjusted based on patient lifestyle and eating patterns 1

Intensification Pathway

If once-daily dosing fails to achieve glycemic targets after appropriate titration 1:

  • Consider advancing to twice-daily Ryzodeg administration 1
  • Base intensification decisions on A1C levels, prandial glucose patterns, and meal distribution throughout the day 1
  • Alternative intensification options include adding separate prandial insulin or transitioning to basal-bolus regimens 1

Common Pitfalls to Avoid

Do not use weight-based dosing for initial Ryzodeg prescription in insulin-naïve patients—the fixed 10-unit starting dose is appropriate regardless of body weight 1. This differs from traditional basal insulin initiation (which typically uses 0.1-0.2 units/kg/day) because Ryzodeg contains both basal and prandial components 2, 3.

Avoid premature intensification—ensure adequate titration of once-daily dosing before advancing to twice-daily administration 1. Many patients achieve targets with once-daily dosing when properly titrated 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.